Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 20/20 | 0.52 |
| ▸ | VEGFA | P15692 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ARNT | P27540 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865427 | 0.79 | EPAS1 (0.72) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865407 | 0.79 | EPAS1 (0.72) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865226 | 0.79 | EPAS1 (0.49) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865442 | 0.78 | EPAS1 (0.44) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL20253145 | 0.77 | EPAS1 (0.65) | EPAS1VEGFA | |
| SCHEMBL19865439 | 0.76 | EPAS1 (0.38) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865405 | 0.69 | VEGFA (0.63) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865406 | 0.69 | VEGFA (0.63) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865224 | 0.69 | VEGFA (0.37) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18078463 | 0.69 | EPAS1 (0.53) | EPAS1VEGFAARNT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2018031680-A1 | NOVEL COMPOUNDS, USES AND METHODS FOR THEIR PREPARATION | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | HIF1AN, EGLN2, EGLN3 | EPAS1 30/4885VEGFA 2429/4885CYP2C9 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.